Edith P. Mitchell

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile

0.476Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

JCO Precision Oncology(2024)10.1200/po.23.00407

Top 40%

0.476DataRank

Top 40%10 citations

Alain C. Mita, Zihan Wei, Heather H. Cheng, Edith P. Mitchell, John J. Wright +16 more

Papers

Driven by 23 papers — median percentile 0. Top paper: “Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W”.

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

Journal of Clinical Oncology(2020)10.1200/jco.19.02630

N/A

4.7DataRank · unranked

179 citations

Fangxin Hong, Christos Vaklavas, Heather H. Cheng, Peter S. Hammerman, Edith P. Mitchell +17 more

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2

JCO Precision Oncology(2023)10.1200/po.22.00421

N/A

0.656DataRank · unranked

16 citations

Yael Flamand, Melissa Wilson, Jason J. Luke, Hussein A. Tawbi, Fangxin Hong +19 more

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

JCO Precision Oncology(2024)10.1200/po.23.00407

Top 40%

0.476DataRank

Top 40%10 citations

Alain C. Mita, Zihan Wei, Heather H. Cheng, Edith P. Mitchell, John J. Wright +16 more

Phase II Study of Palbociclib (PD-0332991) in CCND1 , 2 , or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2150

N/A

0.457DataRank · unranked

20 citations

Fangxin Hong, Richard S. Finn, Angela DeMichele, Edith P. Mitchell, James A. Zwiebel +18 more

ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer

Journal of Clinical Oncology(2024)10.1200/jco.24.00526

N/A

0.442DataRank · unranked

11 citations

Fengmin Zhao, Tarah J. Ballinger, Sofia F. Garcia, Fei Shen, Shamsuddin Virani +19 more

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2 -Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-0633

N/A

0.414DataRank · unranked

9 citations

Victoria Wang, Jaime B. Hyman, Petros Grivas, Edith P. Mitchell, John Wright +17 more

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2137

N/A

0.330DataRank · unranked

8 citations

Opeyemi A. Jegede, Victor T. Chang, Todd C. Skaar, Jeffrey L. Berenberg, Ranveer Nand +15 more

Medical student clinical cultural awareness in cancer care of sexual gender minority patients

Patient Education and Counseling(2024)10.1016/j.pec.2024.108395

N/A

0.165DataRank · unranked

2 citations

Annika G. Samuelson, Jaileene Pérez‐Morales, Matthew B. Schabath, Edith P. Mitchell, Cherry Au

Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

European Journal of Cancer(2022)10.1016/s0959-8049(22)01023-1

N/A

0.104DataRank · unranked

1 citations

Zeyuan Song, Scott Gettinger, Edith P. Mitchell, JJ Wright, Jeff Moscow +14 more

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E

JCO Precision Oncology(2024)10.1200/po.23.00454

N/A

0.104DataRank · unranked

1 citations

Zihe Song, Helena A. Yu, Lecia V. Sequist, Christine M. Lovly, Edith P. Mitchell +17 more

Corona Virus: Global Pandemic Causing World-Wide Shutdown

Journal of the National Medical Association(2020)10.1016/j.jnma.2020.03.015

N/A

0DataRank · unranked

22 citations

Edith P. Mitchell

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3443

N/A

0DataRank · unranked

90 citations

Fengmin Zhao, Marcus Smith Noel, Gregory J. Riely, Edith P. Mitchell, John J. Wright +15 more

Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3506

N/A

0DataRank · unranked

5 citations

Fengmin Zhao, Dustin A. Deming, Edith P. Mitchell, John Joseph Wright, L. Austin Doyle +15 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100

Top 100%

0DataRank

Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100.v1

Top 100%

0DataRank

Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Effect of microRNA-21 blockade in human triple negative breast cancer allografts on progression and immune checkpoint proteins.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e13097

N/A

0DataRank · unranked

0 citations

Vilas Desai, Miguel M. Castro, Edith P. Mitchell, Eric Wickstrom, Yuanyuan Jin

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djz245

N/A

0DataRank · unranked

231 citations

Robert J. Gray, Alice P. Chen, Shuli Li, David R. Patton, Stanley R. Hamilton +35 more

Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3108

N/A

0DataRank · unranked

3 citations

Zihan Wei, David S. Hong, Edith P. Mitchell, James A. Zwiebel, Elad Sharon +15 more

A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3087

N/A

0DataRank · unranked

8 citations

Opeyemi A. Jegede, Marjorie G. Zauderer, Edith P. Mitchell, James A. Zwiebel, Robert J. Gray +13 more

Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.12003

N/A

0DataRank · unranked

2 citations

Opeyemi A. Jegede, Victor T. Chang, Todd C. Skaar, Jeffrey L. Berenberg, Ranveer Nand +15 more

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

npj Precision Oncology(2022)10.1038/s41698-022-00256-w

N/A

0DataRank · unranked

43 citations

Zihan Wei, Ranee Mehra, Alice T. Shaw, Christopher H. Lieu, Patrick M. Forde +24 more

“I need more knowledge”: Qualitative analysis of oncology providers’ experiences with sexual and gender minority patients

Frontiers in Psychology(2022)10.3389/fpsyg.2022.763348

N/A

0DataRank · unranked

14 citations

Edith P. Mitchell, Lynne I. Wagner, Melissa A. Simon, Ruth C. Carlos, Bruce J. Giantonio +3 more

Phase II study of sunitinib in tumors with c-KIT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol V

European Journal of Cancer(2022)10.1016/s0959-8049(22)01026-7

N/A

0DataRank · unranked

3 citations

Zeyuan Song, A. Poklepovic, Eric A. Collisson, Edith P. Mitchell, James Zweibel +15 more

Edith P. Mitchell

Indexed papers

Top data-sharing exemplar

Papers